Clinical trials: Recurrence Hepatocellular Carcinoma
Liver Cancer
Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection
This prospective non-randomized controlled trial aims to determine whether autotransfusion of red blood cells salvaged before liver resection is associated with the recurrence-free survival in patients with hepatocellular…
- Trial name
- AT/HCC (NCT02654028)
- Testing
- Autotransfusion, Control group
- Where
- China
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Liver Cancer
National Registry and Blood Bank of Patients With Liver Cancer
RATIONALE: Gathering health information about patients with liver cancer over time may help doctors learn more about the disease and may help the study of cancer in the future.
- Trial name
- NCT00482365
- Testing
- biologic sample preservation procedure, medical chart review, Patient interview
- Where
- 3 sites in United States
- Volunteers
- 151 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
Liver transplantation is the standard treatment for patients with early-stage Hepatocellular Carcinoma (HCC). Currently, important treatment decisions, like the selection of patients for transplantation, are made on crude, static…
- Trial name
- PETMRIinHCC (NCT03839706)
- Testing
- PET MRI
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
The purpose of the study is to observe the effect of sorafenib combined with aspirin in preventing the recurrence in high-risk patients with hepatocellular carcinoma.
- Trial name
- NCT02748304
- Testing
- control, sorafenib, aspirin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan.
- Trial name
- NCT06354387
- Testing
- Alectinib (Alecensa), Nivolumab (Opdivo)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- China Medical University Hospital
Liver Cancer
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well temsirolimus works in treating patients with advanced liver…
- Trial name
- NCT01079767
- Testing
- temsirolimus
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Liver Cancer
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00483405)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
Pembrolizumab as Neoadjuvant Treatment in HCC
The aim of this study is to elucidate the utility of the immune checkpoint inhibitor pembrolizumab in preventing the recurrence of HCC when administered before and after curative surgery or ablation.
- Trial name
- NCT03337841
- Testing
- Pembrolizumab
- Volunteers
- 50 people
- Sponsor
- Kindai University
Carcinoma, Hepatocellular
Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
Antiviral therapy for HBV may play an important role here, as a large observation study from Taiwan reported that the use of nucleos(t)ide analogues (NUC) was associated with 33% reduction in HCC recurrence.
- Trial name
- POWER (NCT02308319)
- Testing
- Tenofovir disoproxil fumarate
- Volunteers
- 124 people
- Sponsor
- Samsung Medical Center
Brain and Central Nervous System Tumors, Kidney Cancer
MT2004-30: Tomotherapy for Solid Tumors
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation…
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma
- Trial name
- NCT00623077
- Testing
- filgrastim, busulfan, etoposide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hepatocellular Carcinoma (HCC)
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical…
- Trial name
- NCT05213637
- Testing
- Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chinese PLA General Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Hepatocellular Cancer
Major RF Ablations of Hepatomas Under MR Thermometry Monitoring
Object of the study: To assess the effectiveness of MR temperature monitoring of RFA of large hepatocellular carcinomas (HCC) (≥ 5 cm) in terms of complete tumor necrosis rate achieved and in term of reduction of the number of…
- Trial name
- ARMTICH (NCT01486134)
- Testing
- Multipolar Radiofrequency ablation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma (HCC)
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
This retrospective observational study aims to evaluate whether artificial intelligence (AI) models can predict aggressive recurrence in patients who underwent liver resection for early-stage hepatocellular carcinoma (HCC).
- Trial name
- NCT07030842
- Testing
- liver resection
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
This study will compare and analyze the difference between hepatectomy at deep and complex sites(adjacent to major blood vessels) of patients with HCC and PRFA prognosis, recovery after treatment as well as incidence of…
- Trial name
- NCT00814242
- Testing
- surgical resection, percutaneous radiationfrequency ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
This phase II trial is studying how well bortezomib works in treating patients with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00077441
- Testing
- bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
- Trial name
- NCT00012324
- Testing
- doxorubicin hydrochloride, nolatrexed dihydrochloride
- Where
- 42 sites in United States, Canada and 1 more
- Sponsor
- Eximias Pharmaceutical
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation
This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC.
- Trial name
- NCT03490461
- Testing
- Statin
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Yonsei University